JP2011515490A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515490A5
JP2011515490A5 JP2011502032A JP2011502032A JP2011515490A5 JP 2011515490 A5 JP2011515490 A5 JP 2011515490A5 JP 2011502032 A JP2011502032 A JP 2011502032A JP 2011502032 A JP2011502032 A JP 2011502032A JP 2011515490 A5 JP2011515490 A5 JP 2011515490A5
Authority
JP
Japan
Prior art keywords
vaccine
cldc
adjuvanted
fish
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011502032A
Other languages
English (en)
Japanese (ja)
Other versions
JP5759890B2 (ja
JP2011515490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/038307 external-priority patent/WO2009120811A1/en
Publication of JP2011515490A publication Critical patent/JP2011515490A/ja
Publication of JP2011515490A5 publication Critical patent/JP2011515490A5/ja
Application granted granted Critical
Publication of JP5759890B2 publication Critical patent/JP5759890B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011502032A 2008-03-25 2009-03-25 カチオン性脂質−dna複合体(cldc)の投与による免疫応答の増強 Expired - Fee Related JP5759890B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3938108P 2008-03-25 2008-03-25
US61/039,381 2008-03-25
PCT/US2009/038307 WO2009120811A1 (en) 2008-03-25 2009-03-25 Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)

Publications (3)

Publication Number Publication Date
JP2011515490A JP2011515490A (ja) 2011-05-19
JP2011515490A5 true JP2011515490A5 (enExample) 2012-05-17
JP5759890B2 JP5759890B2 (ja) 2015-08-05

Family

ID=40791017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502032A Expired - Fee Related JP5759890B2 (ja) 2008-03-25 2009-03-25 カチオン性脂質−dna複合体(cldc)の投与による免疫応答の増強

Country Status (6)

Country Link
US (1) US8945590B2 (enExample)
EP (1) EP2257306B1 (enExample)
JP (1) JP5759890B2 (enExample)
BR (1) BRPI0910036B8 (enExample)
CA (1) CA2719614C (enExample)
WO (1) WO2009120811A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945590B2 (en) 2008-03-25 2015-02-03 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
ES2550181T3 (es) * 2009-05-14 2015-11-05 Bayer Intellectual Property Gmbh Respuesta inmunitaria reforzada en especies aviares
US9089537B2 (en) * 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
PL2654785T3 (pl) * 2010-12-22 2019-09-30 Bayer Intellectual Property Gmbh Wzmocniona odpowiedź immunologiczna u gatunków wołowatych
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EP3110940A1 (en) 2014-02-28 2017-01-04 Bayer Animal Health GmbH Immunostimulatory plasmids
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR20180035860A (ko) * 2015-07-31 2018-04-06 바이엘 애니멀 헬스 게엠베하 수생 종에서의 향상된 면역 반응
US11439703B2 (en) 2015-07-31 2022-09-13 ELANCO US, Inc. Enhanced immune response in porcine species
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10918709B2 (en) * 2016-10-31 2021-02-16 Eyegene Inc. Immune modulator and vaccine composition containing the same
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US6121247A (en) 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
EP1006999A2 (en) * 1997-07-08 2000-06-14 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
EP1009413B1 (en) 1997-09-05 2007-02-14 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or treating asthma
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20090208781A1 (en) * 2008-02-19 2009-08-20 Skinner George A Method for operating a fuel cell system
WO2009105283A1 (en) 2008-02-24 2009-08-27 Govt. Of The United States Of America, As Represented By The Sec., Dept. Of Health And Human Service Use of immunogenic compositions for the treatment or prevention of pathogen infections
US8945590B2 (en) 2008-03-25 2015-02-03 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
US20100137235A1 (en) 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
ES2550181T3 (es) 2009-05-14 2015-11-05 Bayer Intellectual Property Gmbh Respuesta inmunitaria reforzada en especies aviares

Similar Documents

Publication Publication Date Title
JP2011515490A5 (enExample)
EP2257306B1 (en) Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
EP2720717B1 (en) Vaccine adjuvant composition comprising inulin particles
US8216595B2 (en) Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant
RU2020117033A (ru) Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение
JP2009539965A5 (enExample)
Riese et al. Vaccine adjuvants: key tools for innovative vaccine design
CN111315407A (zh) 一种广谱抗流感疫苗免疫原及其应用
JP2009511084A5 (enExample)
JP2016506416A5 (enExample)
JP2004527264A5 (enExample)
RU2008119501A (ru) Функциональные вирусоподоюные частицы гриппа (vlps)
JP2010537961A5 (enExample)
Lee et al. Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use
US20150064216A1 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
JP2010520284A5 (enExample)
JP2019510064A5 (enExample)
JP7618632B2 (ja) 経鼻b型肝炎ワクチン組成物およびその製造方法
JP2016520077A5 (enExample)
KR102654379B1 (ko) 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물
RU2018103757A (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
Webster Potential advantages of DNA immunization for influenza epidemic and pandemic planning
US20130039973A1 (en) Viral Immunogenic Compositions
ES2615120T3 (es) Adyuvantes peptídicos
EA200870361A1 (ru) Интраназальное или ингаляционное введение виросом